NCT06096948 (NEX-ENDOHS) is a NA clinical trial of NEXPOWDER-ENDOHS in Gastro Intestinal Bleeding, sponsored by Erasme University Hospital.

Who is sponsoring NCT06096948?

NCT06096948 is sponsored by Erasme University Hospital.

What drugs are being tested in NCT06096948?

Interventions in NCT06096948: NEXPOWDER-ENDOHS.

What condition does NCT06096948 study?

NCT06096948 studies Gastro Intestinal Bleeding, Polyps.

Is NCT06096948 still recruiting?

NCT06096948 is currently status unknown. Last updated 24 October 2023.

Last reviewed 2023-10-24 · How we verify

NCT06096948: NEX-ENDOHS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nexpowder to Prevent Delayed Bleeding After Endoscopic Resection

Status unknown NA Last updated 24 October 2023

What this trial tests

NA trial testing NEXPOWDER-ENDOHS in Gastro Intestinal Bleeding in 50 participants. Status unknown.

Timeline

15 October 2023

Primary endpoint
30 April 2024

30 July 2024

Quick facts

Lead sponsor	Erasme University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	50
Start date	15 October 2023
Primary completion	30 April 2024
Estimated completion	30 July 2024
Sites	12 locations across Belgium, Netherlands

Drugs / interventions tested

NEXPOWDER-ENDOHS

Conditions studied

Gastro Intestinal Bleeding — all drugs for Gastro Intestinal Bleeding →
Polyps — all drugs for Polyps →

Sponsor

Erasme University Hospital

Who can join

18 and older, any sex, with Gastro Intestinal Bleeding or Polyps. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Safety and effectiveness of a new hemostatic system to prevent delayed bleeding after endoscopic resection in a selected high-risk population (NEXPOWDER- ENDOHS). Indication: Patients with indication of endoscopy resection by endoscopic mucal resection (EMR) or endoscopic submucosal dissection (ESD) with high risk of delayed bleeding (≥5%). Hypotheses: The use of NexpowderTM after upper and lower gastrointestinal ESD or EMR of ≥20mm in high-risk population will prevent and decrease delayed bleeding to less than 5%.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Erasme University Hospital trials

Trials by the same sponsor.

NCT07532733 — Respiratory and Haemodynamic Effects of Conscious Sedation With Dexmedetomidine for a TAVI Procedure · NA · not yet recruiting
NCT07532681 — Effect of Early Versus Late Surgical Intercostal Block on Postoperative Pain Relief Following Video-Assisted Thoracic Su · NA · not yet recruiting
NCT07457879 — Impact of the Reimbursement of Fibrinogen in Cardiac Surgery · not yet recruiting
NCT07184593 — Nucleosome Monitoring Relevance for Outcome Prediction in Critically Ill Patients · not yet recruiting
NCT07369232 — Cerebral Hemodynamic Effects of Oxygen and Antioxidants (CHEOXANT) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06096948 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erasme University Hospital
Last refreshed: 24 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06096948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing